Abstract
Objectives:
The echinoderm microtubule-associated protein-like 4 (EML4) gene and anaplastic lymphoma kinase (ALK) gene fusion is the most common ALK rearrangement in non-small-cell lung cancer (NSCLC). SQSTM1 (exon 5)–ALK (exon 20) fusion in patients with NSCLC was first identified in 2015. However, the treatment of lung adenocarcinoma patients with SQSTM1–ALK fusion has not been previously reported. In this study, we report for the first time an SQSTM1–ALK fusion in a stage-IV lung adenocarcinoma patient who had a variable response after sequential treatment with alectinib, ensartinib, lorlatinib, and brigatinib.
Materials and methods:
The biopsy specimen was subjected to hematoxylin–eosin (HE) staining, immunohistochemistry (IHC), and next-generation sequencing (NGS).
Results:
The patient responded to alectinib as first-line treatment and achieved stable disease for 16 months without significant toxicity. Ensartinib appeared to have a better effect on brain metastases. As third-line therapy, lorlatinib resulted in a progression free survival (PFS) of 15 months. In addition, as fourth-line therapy, brigatinib yielded a PFS of only 2 months.
Conclusion:
This is the first report of a patient with SQSTM1–ALK fusion who experienced different responses after treatment with alectinib, ensartinib, lorlatinib, and brigatinib. We hope that this case provides clinical evidence to guide treatment strategies for this rare variant and further supports the individualized application of ALK-tyrosine kinase inhibitors (TKIs) in patients with non-classical fusions.
Introduction
Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small-cell lung cancer (NSCLC) is currently the most common type of lung cancer, with lung adenocarcinoma being the most common histology of NSCLCs (). However, the identification of driver mutations, including epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements, has dramatically changed the management of NSCLC. Moreover, with the development of next-generation sequencing (NGS) technologies, the identification of new mutations is increasing the number of treatment options available to patients.
ALK rearrangement is a well-recognized oncogenic driver in NSCLC, and its rearrangement is observed in 3.4%–6.7% of NSCLC patients (; ). To date, more than 90 types of ALK fusions have been identified around the world, with the most common type being a fusion between the ALK and the echinoderm microtubule-associated protein-like 4 (EML4) gene (). The first-generation ALK-tyrosine kinase inhibitor (TKI) crizotinib transformed ALK-positive NSCLC treatment, but resistance inevitably arises through ALK-dependent (secondary mutations and gene amplification) and ALK-independent (bypass pathways and small-cell transformation) mechanisms. Second-generation TKIs such as alectinib, ceritinib, ensartinib, and brigatinib were developed to address crizotinib resistance, with alectinib demonstrating 3-fold longer PFS than crizotinib in phase-III trials and becoming the first-line therapy (). The domestic second-generation TKI ensartinib, approved in China in November 2020, offers superior blood–brain barrier penetration, making it ideal for brain metastases (). However, resistance to second-generation TKIs, often from ALK kinase domain mutations (e.g., G1202R and I1171N/S/T), necessitated the third-generation TKI lorlatinib. Sequential therapy with these agents is crucial for managing rare mutations and overcoming TKI resistance. Meanwhile, the rapid advances in next-generation sequencing (NGS) have enabled the detection of an increasing number of ALK fusions, such as the SQSTM1–ALK fusion. The SQSTM1–ALK fusion has been most commonly observed in large B-cell lymphomas (). identified a novel translocation partner, SQSTM1 (exon 5)–ALK (exon 20), in patients with NSCLC using NGS. However, the sequential therapy for SQSTM1–ALK fusion lung adenocarcinoma patients has not been previously reported. Only two relevant studies have been published to date. One of these studies detailed that when alectinib was used as a first-line therapy, it led to a partial response (PR) after 7 months of treatment (). The other study indicated that ensartinib managed to maintain a PR state even after 6 months of treatment (). Notably, neither of these studies provided any information on the progression-free survival (PFS) and possible therapeutic sequences. However, for the first time, we report an SQSTM1–ALK fusion in a patient with stage-IV lung adenocarcinoma who experienced variable response after sequential treatment with alectinib, ensartinib, lorlatinib, and brigatinib. This study also marks the first reported application of lorlatinib and brigatinib in the treatment of this specific mutation site in SQSTM1–ALK fusion lung adenocarcinoma.
Case presentation
In January 2021, a 43-year-old man with a history of smoking presented to our hospital with chest pain and shortness of breath lasting 2 weeks. There was no relevant past medical history or family history. Diminished breath sounds in the left lung field were noted on physical examination. High-resolution computed tomography (HRCT) showed that the bronchus in the left lower lobe was narrowing with a mass of increased density and metastases of hilar and mediastinal lymph nodes, bilateral supraclavicular lymph nodes, and left pleural metastases. Emission computed tomography (ECT) demonstrated bone metastases at the first, eighth, and ninth thoracic vertebrae, which is consistent with a clinical stage of T4N3M1c (IVB). The patient’s ECOG performance status (PS) was 0. Serum tumor marker results showed elevated levels of CEA (10.79 ug/L; reference value <5 ug/L). The cytology of the pleural fluid was positive, showing a small focus of atypical cells, which was most likely lung adenocarcinoma. A lymph node biopsy was performed using endobronchial and transbronchial needle aspiration (EBUS–TBNA). Pathology revealed lymph node metastasis of lung adenocarcinoma (Figure 1). Immunohistochemical (IHC) staining was positive for TTF-1, napsin A, and CK7. P40 and CK20 were negative. Formalin-fixed paraffin-embedded (FFPE) tumor samples were analyzed by DNA next-generation sequencing (NGS, 139 gene panel, Geneseeq Technology Inc.) and RNA NGS (117-gene panel, Geneseeq Technology Inc.) The results of DNA and RNA sequencing identified an SQSTM1–ALK (exon 6-exon 20) fusion in the patient (Figure 2).
FIGURE 1
FIGURE 2
The patient started to receive alectinib (600 mg twice) on 28 February 2021 and bisphosphonates monthly. After 8 weeks, the CT scan demonstrated reduced tumor size and smaller lymph nodes and left pleural nodules compared with those in the previous examination, and the evaluation of therapeutic efficiency indicated partial response (PR) (Figure 3). All efficacy evaluations were performed according to the RECIST 1.1 criteria. A CT scan on 26 August 2021 showed the metastases of the hilar and mediastinal lymph nodes, and the bilateral supraclavicular lymph nodes were vanishing. Follow-up CT scans showed PR until June 2022. A CT scan on 22 June 2022 showed the thickening of the left pleural nodules, and the magnetic resonance imaging (MRI) of the brain showed one new brain metastasis of the left frontal cortex (measuring approximately 3–4 mm in diameter). The evaluation of therapeutic efficiency indicated progressive disease (PD) (Figure 3). Serum oncological markers’ results showed almost normal levels of CEA (1.37 ug/L; reference value <5 ug/L). Percutaneous transthoracic CT-guided biopsies of the left pleural lesions were negative. We conducted ctDNA analysis using DNA NGS (139-gene panel, Geneseeq Technology Inc.) with peripheral blood in July 2022, and the results still showed an SQSTM1–ALK (exon 6-exon 20) fusion in the patient. At that time, clinical evidence for sequential therapy in rare SQSTM1–ALK fusion was limited, so chemotherapy was considered an option, consistent with the NCCN guidelines (), which recommend chemotherapy for TKI-progressing patients without clear targeted alternatives. We recommended re-biopsy and chemotherapy. However, the patient rejected the recommendation. Considering the higher blood–brain barrier and intracerebral distribution, the patient started to receive ensartinib (225 mg daily) on 12 July 2022. On 6 September 2022, a CT scan showed the tumor progression in the lungs; however, the MRI of the brain showed that the brain metastases had disappeared. The evaluation of therapeutic efficiency still indicated PD (Figure 3). As the patient again refused re-biopsy, treatment with lorlatinib (100 mg once daily) was initiated on 9 September 2022. Only grade-1 hypercholesterolemia and liver function impairment occurred during lorlatinib treatment. Until November 2023, during the period of lorlatinib treatment, the lesions showed stable conditions. In November 2023, upon detecting disease progression (manifested by significant enlargement of the pleural nodule in the dorsal segment of the left lower lobe), repeat pathological biopsy and genetic testing were conducted. The results confirmed that the patient still had SQSTM1–ALK lung adenocarcinoma, and PD-L1 expression testing was also performed and was positive (TPS = 40%). Following a comprehensive evaluation by our medical team, we recommended a change in the treatment regimen. However, in the absence of obvious symptoms, the patient requested to continue the current medication and independently sought traditional Chinese medicine treatment. However, disease progression was confirmed by April 2024 CT findings, which showed significant enlargement of the pleural nodule in the dorsal segment of the left lower lobe. In addition, the treatment was switched to brigatinib (180 mg once daily). However, disease progression was re-detected in June 2024, manifested by the enlargement of the pleural nodule in the left lower lobe and the concurrent enlargement of other nodules in the left oblique fissure and pleura. Consistent with previous instances, after a comprehensive evaluation, our team recommended that the patient switch to a different treatment regimen. However, as the patient was unwilling to undergo chemotherapy, they insisted on continuing brigatinib treatment and additionally started taking traditional Chinese medicine. Nevertheless, the disease was still advancing when the patient was evaluated in March 2025. Moreover, the patient experienced severe shortness of breath. At this point, the treatment was changed to a combination of chemotherapy and antiangiogenic therapy.
FIGURE 3
Initially, the patient felt hopeful during alectinib treatment as the disease stabilized, but anxiety grew with tumor progression. Ensartinib relieved concerns about brain metastases, and lorlatinib brought another period of stability. However, brigatinib’s short-lived efficacy was disappointing. Throughout the treatment, the patient remained determined to fight, yet the continuous treatment changes and disease progressions took an emotional toll, leaving him hoping for more effective treatments.
Discussion
To our knowledge, this is the first reported case of a lung adenocarcinoma patient with a rare ALK rearrangement (SQSTM1–ALK) who was successfully treated with alectinib, ensartinib, lorlatinib, and brigatinib sequentially. In this study, we report the novel therapeutic application of lorlatinib and brigatinib in a patient with SQSTM1–ALK fusion-positive lung adenocarcinoma harboring this unique mutation. Even as the third-line therapy, lorlatinib has a PFS of 15 months.
The SQSTM1 gene, located on 5q35, encodes a ubiquitin-binding protein that mediates the NF-kB pathway activation and participates in oxidative stress response and autophagy (; ). Previously, mutations of SQSTM1 were reported in Paget bone disease (). used NGS to identify a novel translocation partner, SQSTM1 (exon 5)–ALK (exon 20), in patients with NSCLC. reported a patient with an inflammatory myofibroblastic tumor harboring an SQSTM1–ALK fusion who exhibited a marked response to alectinib treatment, which was sustained for 17 months following systemic therapy initiation without significant adverse events. To date, only two studies have reported treatment outcomes for SQSTM1–ALK fusion-positive lung adenocarcinoma: one demonstrated a durable partial response (PR) after 7 months of first-line alectinib therapy (), while another showed sustained PR for 6 months with ensartinib therapy (). Clinical evidence for SQSTM1–ALK fusion-positive lung adenocarcinoma remains limited, especially for lorlatinib and brigatinib.
Due to the lack of clinical evidence for targeted drug use in this rare mutation, we also referred to the targeted drug selection strategies for other rare ALK mutations and common ALK mutations when formulating the treatment regimen. In most cases of uncommon ALK fusions (; ; ), alectinib is preferred and has shown favorable efficacy. In addition (), in cases with the novel LMO7–ALK fusion, alectinib was administered first with a PFS of 2 months, followed by ensartinib, which achieved a PFS of 18 months. The treatment regimen for our patient with a rare SQSTM1–ALK fusion is similar to those used for other patients with rare ALK mutations mentioned above. In addition, for common ALK fusion-positive lung adenocarcinoma patients, second-generation ALK-TKIs such as alectinib were approved as first-line treatments due to their superior systemic and CNS efficacy and favorable safety compared to chemotherapy and crizotinib (). The ALEX study showed that alectinib outperformed crizotinib in PFS regardless of EML4–ALK variants (). , found that the most common mutations following alectinib treatment failure are G1202R and I1171N/S/T. In addition, mutations at the L1198, V1180, I1171N, and L1196 sites affect conformational changes in the ATP-binding pocket and hinge region, thereby altering the “latching” interaction between alectinib and ALK. For instance, two “gatekeeper” mutations (V1180L and ALK L1196M/Q) and I1171T/N/S mutations confer resistance to both alectinib and crizotinib but remain sensitive to later-generation inhibitors such as ceritinib, brigatinib, and lorlatinib () (; ). Another second-generation TKI, ensartinib, is 10-fold more potent than crizotinib in inhibiting the growth of ALK-positive lung cancer cells. The eXalt3 trial demonstrated its superiority over crizotinib in PFS and its intracranial prophylactic role () (). In our patient, ensartinib also showed favorable therapeutic effects on brain lesions. However, studies have shown that the most common secondary resistance mutations in patients with disease progression after ensartinib treatment are G1269A, G1202R, and E1210K. Among these, G1269A remains sensitive to other second-generation inhibitors, while G1202R demonstrates the most definite response to lorlatinib (; ; ). Lorlatinib, a third-generation ALK-TKI, was developed to overcome resistance to earlier-generation TKIs (; ) and achieve marked central nervous system (CNS) penetration. A global phase-II study showed an overall response rate (ORR) of 47% and an intracranial response rate of 63% in patients pre-treated with at least one ALK-TKI () (). Brigatinib is a second-generation ALK-TKI. The ALTA trial series confirmed its efficacy (), and intriguingly, it demonstrated in vitro inhibitory activity against 17 ALK mutants associated with resistance to crizotinib, ceritinib, and alectinib. Specifically, brigatinib showed more than 3-fold greater potency than alectinib against L1152R, I1171N, V1180L, L1196M, G1202R, and G1269A mutations, and it even exhibited superior activity compared to lorlatinib against the G1269A mutation (). After lorlatinib progression, some compound mutations (e.g., V1185L + L1196M) can re-sensitize to first-/second-generation TKIs. Additionally, brigatinib achieves a 7-month mPFS even in patients previously treated with ceritinib, alectinib, or at least two ALK-TKIs (; ; ). Moreover, most studies have reported the SQSTM1 (exon 5)–ALK (exon 20) fusion. In contrast, our case’s SQSTM1 (exon 6)–ALK (exon 20) fusion, with the breakpoint in SQSTM1 exon 6 (closer to the coding region), may alter the fusion protein’s conformation and impair ALK-TKI binding. Such variants may show reduced sensitivity to drugs such as brigatinib due to steric hindrance from the fusion site’s proximity to the ALK kinase domain (). Unfortunately, it did not yield a favorable response. Since no tissue genetic testing was performed after lorlatinib resistance, it cannot be ruled out that, first, there was ALK-independent bypass resistance; second, brigatinib did not cover the resistance sites specific to ALK itself. Due to the patient’s refusal to undergo a third genetic test, chemotherapy was ultimately initiated.
STAT3 is a key regulator of ALK-induced growth and survival (; ; ). SQSTM1–ALK expression is associated with high STAT3 phosphorylation at Tyr705, which is crucial for its dimerization and DNA binding (). Alectinib strongly inhibits ALK and its downstream signaling molecules, including STAT3 (). Moreover, ALK-rearranged lung cancer cell survival after ALK inhibition is mainly dependent on the STAT3 activity (). This is probably one of the reasons why lung adenocarcinoma patients with SQSTM1–ALK fusion are successfully being treated with alectinib, ensartinib, and lorlatinib. In addition, we speculate that the differential efficacy of different drugs may be related to the inhibition efficiency of ALK phosphorylation and the blood–brain barrier permeability.
Conclusion
This is the first report on a patient with SQSTM1–ALK fusion who had a different response after sequential treatment with alectinib, ensartinib, lorlatinib, and brigatinib. This case is the first to report the response data of SQSTM1 (exon6-ALK exon20) fusion to ensartinib and alectinib, providing clinical evidence for the treatment strategy of this rare variant and further supporting the individualized application of ALK-TKIs in patients with non-classical fusions.
Statements
Data availability statement
The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding authors.
Ethics statement
Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.
Author contributions
JG: Data curation, Formal Analysis, Writing ‐ original draft. JZ: Formal Analysis, Writing ‐ original draft, Writing ‐ review and editing. SL: Data curation, Formal Analysis, Methodology, Project administration, Resources, Supervision, Writing ‐ original draft. ZL: Investigation, Methodology, Project administration, Writing ‐ original draft. LH: Funding acquisition, Writing ‐ original draft, Writing ‐ review and editing. YZ: Funding acquisition, Project administration, Resources, Writing ‐ review and editing.
Funding
The author(s) declare that financial support was received for the research and/or publication of this article. This work was supported by the Natural Science Foundation of Guangdong Province, (Project No. 2024A1515013043).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
AminH. M.McDonnellT. J.MaY.LinQ.FujioY.KunisadaK.et al (2004). Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-Positive Anaplastic large cell lymphoma. Oncogene23 (32), 5426–5434. 10.1038/sj.onc.1207703
2
CamidgeD. R.DziadziuszkoR.PetersS.MokT.NoeJ.NowickaM.et al (2019). Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study. J. Thorac. Oncol.14 (7), 1233–1243. 10.1016/j.jtho.2019.03.007
3
ChiarleR.SimmonsW. J.CaiH.DhallG.ZamoA.RazR.et al (2005). Stat3 is required for ALK-Mediated lymphomagenesis and provides a possible therapeutic target. Nat. Med.11 (6), 623–629. 10.1038/nm1249
4
D'AmoreE. S.ViscoC.MeninA.FamengoB.BonviniP.LazzariE. (2013). STAT3 pathway is activated in ALK-Positive large B-cell lymphoma carrying SQSTM1-ALK rearrangement and provides a possible therapeutic target. Am. J. Surg. Pathol.37 (5), 780–786. 10.1097/PAS.0b013e318287791f
5
DescourtR.PerolM.Rousseau-BussacG.PlanchardD.MennecierB.WislezM.et al (2019). Brigatinib in patients with ALK-Positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: a multicentric real-world study (BRIGALK study). Lung Cancer136, 109–114. 10.1016/j.lungcan.2019.08.010
6
EttingerD. S.WoodD. E.AisnerD. L.AkerleyW.BaumanJ. R.BharatA.et al (2022). Non-small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc Netw.20 (5), 497–530. 10.6004/jnccn.2022.0025
7
GainorJ. F.DardaeiL.YodaS.FribouletL.LeshchinerI.KatayamaR.et al (2016). Molecular mechanisms of resistance to First- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov.6 (10), 1118–1133. 10.1158/2159-8290.CD-16-0596
8
HondaK.KadowakiS.KatoK.HanaiN.HasegawaY.YatabeY.et al (2019). Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report. Investig. New Drugs37 (4), 791–795. 10.1007/s10637-019-00742-2
9
HornL.InfanteJ. R.ReckampK. L.BlumenscheinG. R.LealT. A.WaqarS. N.et al (2018). Ensartinib (X-396) in ALK-positive non-small cell lung cancer: results from a first-in-human phase I/II, multicenter study. Clin. Cancer Res.24 (12), 2771–2779. 10.1158/1078-0432.CCR-17-2398
10
HornL.WangZ.WuG.PoddubskayaE.MokT.ReckM.et al (2021). Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: a randomized clinical trial. JAMA Oncol.7 (11), 1617–1625. 10.1001/jamaoncol.2021.3523
11
HornL.WhisenantJ. G.WakeleeH.ReckampK. L.QiaoH.LealT. A.et al (2019). Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer. J. Thorac. Oncol.14 (11), 1901–1911. 10.1016/j.jtho.2019.08.003
12
HuberR. M.Kauffmann-GuerreroD.HoffmannH.FlentjeM. (2021). New developments in locally advanced nonsmall cell lung cancer. Eur. Respir. Rev.30 (160), 200227. 10.1183/16000617.0227-2020
13
IyevlevaA. G.RaskinG. A.TiurinV. I.SokolenkoA. P.MitiushkinaN. V.AleksakhinaS. N.et al (2015). Novel ALK fusion partners in lung cancer. Cancer Lett.362 (1), 116–121. 10.1016/j.canlet.2015.03.028
14
JohnsonT. W.RichardsonP. F.BaileyS.BroounA.BurkeB. J.CollinsM. R.et al (2014). Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h] [2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-Resistant mutations. J. Med. Chem.57 (11), 4720–4744. 10.1021/jm500261q
15
KatayamaR. (2017). Therapeutic strategies and mechanisms of drug resistance in anaplastic lymphoma kinase (ALK)-Rearranged lung cancer. Pharmacol. Ther.177, 1–8. 10.1016/j.pharmthera.2017.02.015
16
Kauffmann-GuerreroD.KahnertK.HuberR. M. (2021). Treatment sequencing for anaplastic lymphoma kinase-rearranged non-small-cell lung cancer. Drugs81 (1), 87–100. 10.1007/s40265-020-01445-2
17
KomatsuM.KageyamaS.IchimuraY. (2012). p62/SQSTM1/A170: physiology and pathology. Pharmacol. Res.66 (6), 457–462. 10.1016/j.phrs.2012.07.004
18
LatifH.LiuS. V. (2020). Novel ALK mutation with durable response to brigatinib-a case report. Transl. Lung Cancer Res.9 (5), 2145–2148. 10.21037/tlcr-20-145
19
LaurinN.BrownJ. P.MorissetteJ.RaymondV. (2002). Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in paget disease of bone. Am. J. Hum. Genet.70 (6), 1582–1588. 10.1086/340731
20
LiM.AnZ.TangQ.MaY.YanJ.ChenS.et al (2021). Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: a case series and literature review. J. Cell. Mol. Med.25 (19), 9476–9481. 10.1111/jcmm.16897
21
LiP.JuX.YangG. (2024). Concomitant double-fusion of PLEKHA7-ALK and INPP5D-ALK reveals favorable alectinib sensitivity in lung adenocarcinoma: a case report and literature review. Discov. Oncol.15 (1), 43. 10.1007/s12672-024-00899-0
22
LinJ.WangW.ChenR.CaoY. (2022). Lung adenocarcinoma with an uncommon CCDC85A-ALK fusion responding to alectinib: a case report. J. Cell. Mol. Med.26 (20), 5326–5329. 10.1111/jcmm.17520
23
LiuZ.WuQ.LiW.LiP.HuangL.WangT.et al (2023). A novel intergenic (between REG3A and CTNNA2-AS1)-ALK fusion responds to alectinib in lung adenocarcinoma. Lung Cancer186, 107386. 10.1016/j.lungcan.2023.107386
24
MakuuchiY.HayashiH.HarataniK.TanizakiJ.TanakaK.TakedaM.et al (2018). A case of ALK-Rearranged non-small cell lung cancer that responded to ceritinib after development of resistance to alectinib. Oncotarget9 (33), 23315–23319. 10.18632/oncotarget.25143
25
NishioM.YoshidaT.KumagaiT.HidaT.ToyozawaR.ShimokawajiT.et al (2021). Brigatinib in Japanese patients with ALK-positive NSCLC previously treated with alectinib and other tyrosine kinase inhibitors: outcomes of the phase 2 J-ALTA trial. J. Thorac. Oncol.16 (3), 452–463. 10.1016/j.jtho.2020.11.004
26
NoeJ.LovejoyA.OuS. H. I.YaungS. J.BordognaW.KlassD. M.et al (2020). ALK mutation status before and after alectinib treatment in locally advanced or metastatic ALK-positive NSCLC: pooled analysis of two prospective trials. J. Thorac. Oncol.15 (4), 601–608. 10.1016/j.jtho.2019.10.015
27
NovelloS.MazièresJ.OhI. J.de CastroJ.MigliorinoM. R.HellandÅ.et al (2018). Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-Positive non-small-cell lung cancer: results from the phase III ALUR study. Ann. Oncol.29 (6), 1409–1416. 10.1093/annonc/mdy121
28
OkadaK.ArakiM.SakashitaT.MaB.KanadaR.YanagitaniN.et al (2019). Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance. EBioMedicine41, 105–119. 10.1016/j.ebiom.2019.01.019
29
OuS. I.ZhuV. W.NagasakaM. (2020). Catalog of 5' fusion partners in ALK-Positive NSCLC circa 2020. JTO Clin. Res. Rep.1 (1), 100015. 10.1016/j.jtocrr.2020.100015
30
PankivS.ClausenT. H.LamarkT.BrechA.BruunJ. A.OutzenH.et al (2007). p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J. Biol. Chem.282 (33), 24131–24145. 10.1074/jbc.M702824200
31
PopatS.BrustugunO. T.CadranelJ.FelipE.GarassinoM. C.GriesingerF.et al (2021). Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer. Lung Cancer157, 9–16. 10.1016/j.lungcan.2021.05.017
32
Rodriguez ArroyoA. B.Mondragón-CardonaA.Pacheco-OrozcoR. A.TamayoA.MorenoJ. C.Baena-ValenciaJ. C. (2024). Partial response to treatment with ALK inhibitor in a patient with SQSTM1-ALK fusion positive lung adenocarcinoma. Eur. J. Case Rep. Intern. Med.11 (12), 004887. 10.12890/2024_004887
33
ShawA. T.SolomonB. J.ChiariR.RielyG. J.BesseB.SooR. A.et al (2019b). ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer. J. Clin. Oncol.37 (16), 1370–1379. 10.1200/JCO.18.02236
34
ShawA. T.SolomonB. J.ChiariR.RielyG. J.BesseB.SooR. A.et al (2019a). Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol.20 (12), 1691–1701. 10.1016/S1470-2045(19)30655-2
35
SodaM.ChoiY. L.EnomotoM.TakadaS.YamashitaY.IshikawaS.et al (2007). Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature448 (7153), 561–566. 10.1038/nature05945
36
SolomonB. J.BesseB.BauerT. M.FelipE.SooR. A.CamidgeD. R.et al (2018). Lorlatinib in patients with ALK-Positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol.19 (12), 1654–1667. 10.1016/S1470-2045(18)30649-1
37
WangP.JiangZ.GuoJ.LiuT.LiuZ.WangD.et al (2024). Case report: treatment with ensartinib shows good response to SQSTM1-ALK fusion in lung adenocarcinoma. Front. Pharmacol.15, 1433894. 10.3389/fphar.2024.1433894
38
WangW. Q.XuT.ZhangJ. J.WangY.WangY.ZhangW.et al (2023). A comprehensive clinical evaluation of first-line drugs for ALK-Positive advanced non-small cell lung cancer. J. Thorac. Dis.15 (4), 1935–1947. 10.21037/jtd-23-380
39
YanagimuraN.TakeuchiS.FukudaK.AraiS.TanimotoA.NishiyamaA.et al (2022). STAT3 inhibition suppresses adaptive survival of ALK-Rearranged lung cancer cells through transcriptional modulation of apoptosis. NPJ Precis. Oncol.6 (1), 11. 10.1038/s41698-022-00254-y
40
YangY.HuangJ.WangT.ZhouJ.ZhengJ.FengJ.et al (2021). Decoding the evolutionary response to ensartinib in patients with ALK-positive NSCLC by dynamic circulating tumor DNA sequencing. J. Thorac. Oncol.16 (5), 827–839. 10.1016/j.jtho.2021.01.1615
41
YangY.ZhouJ.ZhouJ.FengJ.ZhuangW.ChenJ.et al (2020). Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-Positive non-small-cell lung cancer: a multicentre, phase 2 trial. Lancet Respir. Med.8 (1), 45–53. 10.1016/S2213-2600(19)30252-8
42
YoshidaT.KumagaiT.ToyozawaR.KatayamaR.NishioM.SetoT.et al (2023). Brigatinib in Japanese patients with ALK-Positive non-small-cell lung cancer: final results of the phase 2 J-ALTA trial. Cancer Sci.114 (9), 3698–3707. 10.1111/cas.15888
43
YoshimuraY.KurasawaM.YorozuK.PuigO.BordognaW.HaradaN. (2016). Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-Positive NSCLC cell line harboring G1269A mutation: efficacy of alectinib against ALK G1269A mutated cells. Cancer Chemother. Pharmacol.77 (3), 623–628. 10.1007/s00280-016-2977-y
44
ZamoA.ChiarleR.PivaR.HowesJ.FanY.ChilosiM.et al (2002). Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene21 (7), 1038–1047. 10.1038/sj.onc.1205152
Summary
Keywords
lung adenocarcinoma, SQSTM1–anaplastic lymphoma kinase fusion, anaplastic lymphoma kinase inhibitors, case report, treatment
Citation
Gu J, Zhang J, Li S, Lin Z, Huang L and Zhou Y (2025) Case Report: Treatment response of SQSTM1–ALK fusion lung adenocarcinoma to multiple ALK inhibitors. Front. Pharmacol. 16:1608080. doi: 10.3389/fphar.2025.1608080
Received
08 April 2025
Accepted
22 July 2025
Published
23 September 2025
Volume
16 - 2025
Edited by
Lucia Anna Muscarella, Home for Relief of Suffering (IRCCS), Italy
Reviewed by
Domenico Trombetta, IRCCS Casa Sollievo della Sofferenza Hospital, Italy
Marco Donatello Delcuratolo, IRCCS Casa Sollievo della Sofferenza Hospital, Italy
Updates
Copyright
© 2025 Gu, Zhang, Li, Lin, Huang and Zhou.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yanbin Zhou, zhouyb@mail.sysu.edu.cn; Lixia Huang, huanglix3@mail.sysu.edu.cn
† These authors have contributed equally to this work
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.